People | April 06, 2026
Dr Reddy’s elevates Saran PS as Head of Launch Excellence and Program Management
In his new role, Saran will spearhead the end-to-end launch framework for innovation-led portfolio
In his new role, Saran will spearhead the end-to-end launch framework for innovation-led portfolio
He brings extensive cross-functional expertise built through leadership roles
They also differentiated the innovator biologic Semaglutide molecule from newer synthetic or chemical generic versions entering the market
Board approves five-year appointment, subject to shareholder nod through postal ballot
Paid-up equity capital rises to Rs 973.19 crore following allotment to eligible employees
Wholly owned subsidiary KIMS Swastha signs hospital management and sub-lease deal for 210-bed facility, with option to acquire majority stake later
Institute signs four MoUs, launches two products and marks 75 years with renewed focus on lab-to-market commercialisation
Company leadership is framing the move as transformational.
Rs 66 lakh acquisition will support DNA engineering and novel cell-gene therapy alternatives to conventional chemotherapy
The company has highlighted setbacks in Phase II studies while outlining fresh regulatory and late-stage development plans for Fibromun and Nidlegy
Subscribe To Our Newsletter & Stay Updated
